White & Case (Brussels)

Joao Lacerda

White & Case (Brussels)
Associate

Joao Lacerda is an associate in the Brussels office of White & Case and a member of the firm’s EU law practice group. He is currently on secondment to White & Case’s London office. His practice focuses on European competition law, including merger control and antitrust. His expertise includes working on complex international mergers, cartel investigations, abuse of dominance cases, and advising on competition law matters related to horizontal and vertical agreements. Joao assists clients in proceedings before the European Commission and EU courts. He has overseen merger notification processes in a number of jurisdictions, often simultaneously. Prior to joining White & Case, Joao was a public employee at the Brazilian Competition Authority (CADE), where his work covered antitrust investigations and merger control in a broad range of industries, including financial services, automotive and electronic goods. While working for the CADE, Joao acted as delegate of Brazil at the OECD Competition Committee in Paris and undertook training on interrogation techniques applied to antitrust investigations offered by the US Federal Bureau of Investigation. Joao holds an LLM from the University of Cambridge and an LLB from the University of Brasília, having spent one semester studying law and economics at the University of California, Berkeley. He has also completed courses on financial markets at Harvard University and on competition law at the London School of Economics and Political Science (LSE).

Linked authors

White & Case (Brussels)
White & Case (Washington)
White & Case (New York)
White & Case (Riyadh)
White & Case (Washington)

Articles

287 Bulletin

Axel P. Schulz, Fanny Abouzeid, Joao Lacerda The UK Competition Authority along with EU Member States cracks down on excessive pricing in the pharmaceutical sector (Pfizer / Flynn / Actavis)

194

Competition authorities have been traditionally reluctant to pursue excessive pricing cases since many of them had failed on the facts. However, in recent years, there has been a resurgence of the topic in pharma-related cases. In particular, the national competition authorities have led the (...)

Axel P. Schulz, Fanny Abouzeid, Joao Lacerda The French Competition Authority imposes fines totalling €444 million on three laboratories for abuse of collective dominance in the market for the treatment of age-related macular degeneration (Novartis / Roche / Genentech)

57

On 9 September 2020, the French Competition Authority (FCA) imposed fines totalling €444 million on three laboratories (Novartis, Roche and Genentech) for having abused their collective dominant position in the market for the treatment of age-related macular degeneration (AMD). The facts that (...)

Axel P. Schulz, Fanny Abouzeid, Joao Lacerda The UK Competition Authority decides to close its investigation into a pharmaceutical company’s discount scheme, concluding that it is not likely to limit competition (Remicade)

36

On 14 March 2019, the CMA decided to close its investigation into pharmaceutical company MSD’s discount scheme for the medicine Remicade, concluding that it was not likely to limit competition. Previously, the CMA had issued a statement of objections, alleging that MSD abused its dominant (...)

Send a message